birtamimab
prothena
['birtamimab']
#ash22 vital study: in a post-hoc analysis of the patients with stage 4 al amyloidosis, birtamimab + soc led to an improvement in all-cause mortality at 9m, 74% vs 49% in the placebo +soc arm. 
Asst Prof Heme & Onc @WeillCornell specializing in Plasma Cell Disorders